Peptides for Hair Growth: What Human Trials Show vs Minoxidil
Start with our pillar guide: Best Peptides for Skin: Peptide Ingredients in Skincare Ranked by Evidence, or browse all Peptide Science articles.
Peptides for hair growth rest on only a few small human trials. The best include a 22-man placebo-controlled trial of the GPIGS pentapeptide and a 32-person trial in which an acetyl tetrapeptide-3 blend matched 3% minoxidil. Minoxidil has a meta-analysis of randomized trials behind it, so peptides remain the weaker, less-tested option. Evidence: Limited.
Key takeaways
- A 2017 meta-analysis of randomized trials found 5% and 2% minoxidil in men and 2% minoxidil in women all beat placebo for pattern hair loss (P<.00001) (Adil and Godwin, 2017).
- In a 24-week triple-blind trial of 32 people, a blend containing acetyl tetrapeptide-3 raised terminal hair count 8.3% vs 8.7% for 3% minoxidil, with no significant difference (Lueangarun and Panchaprateep, 2020).
- The GPIGS pentapeptide increased the share of thick hairs vs placebo in a 4-month double-blind trial of 22 Japanese men run by Shiseido-affiliated authors (Iwabuchi et al., 2016).
- A 2026 systematic review calls the human GHK-Cu literature "thin and fragmented" (Najafi et al., 2026).
- Thymosin beta-4, the parent protein of TB-500, has hair growth data only in mice and rats (Philp et al., 2004).
For how hair peptides fit among skincare peptides overall, see our peptide ingredients ranked by evidence.
What are peptides for hair growth?
Peptides for hair growth are short chains of amino acids, put in scalp serums and lotions or sold as injectable research compounds, that are meant to support the hair follicle. Most of what's known about how they work comes from cell and organ cultures, not people.
Most of these products target androgenetic alopecia, or pattern hair loss, in which the androgen hormone dihydrotestosterone gradually shrinks the follicles (Adil and Godwin, 2017; Agrawal et al., 2026). Proposed peptide mechanisms differ by ingredient. GPIGS stimulated hair keratinocytes (the cells that build the hair shaft) in lab tests (Iwabuchi et al., 2016). AHK-Cu stimulated dermal papilla cells, the specialized cells at the base of the follicle that drive growth (Pyo et al., 2007).
A 2025 review of popular topical hair actives, including Redensyl, Procapil, Capixyl, Baicapil and AnaGain, found they were mostly tested in combination formulas. It flagged small samples, few comparisons with standard therapy and conflicts of interest (Bikash, 2025). The author declared no conflicts. Evidence: Lab / animal only (for mechanisms).
Do peptides for hair growth actually work?
Some topical peptides for hair growth showed modest benefits in small human trials, but no peptide has the kind of repeated, independent evidence minoxidil has. The ranking below puts each option by the strength of its best human evidence in our sources.
| Rank | Option | Best human evidence in our sources | Compared with | Label |
|---|---|---|---|---|
| 1 | Topical minoxidil | Meta-analysis of randomized trials | Placebo | Well-established |
| 2 | Acetyl tetrapeptide-3 (in a blend) | 1 triple-blind RCT, n=32, 24 weeks | 3% minoxidil | Limited |
| 3 | GHK (with 5-ALA) | 1 RCT, n=45, 6 months | Placebo | Limited |
| 4 | Redensyl + Sepicontrol A5 lotion | 1 single-blind RCT, 41 completed, 24 weeks | Vehicle | Limited |
| 5 | GPIGS pentapeptide | 1 double-blind RCT, n=22, 4 months | Placebo | Early / preliminary |
| 6 | Procapil | Only tested with PRP, n=54 | Another blend + PRP | Limited |
| 7 | AHK-Cu | Human follicles in a dish | None | Lab / animal only |
| 8 | Thymosin beta-4 / TB-500 | Mice and rats | None | Lab / animal only |
| 9 | BPC-157, sermorelin, PP405 | No published hair results in our sources | None | No studies |
| Adil and Godwin, J Am Acad Dermatol, 2017 | RCTs up to Dec 2016 | Varied | 5% and 2% minoxidil (men), 2% (women), 1 mg finasteride, low-level laser | All superior to placebo (P<.00001) |
| Lueangarun and Panchaprateep, J Clin Aesthet Dermatol, 2020 | 32 | 24 weeks | Biochanin A + acetyl tetrapeptide-3 + ginseng vs 3% minoxidil, 1 mL twice daily | Terminal hair count +8.3% vs +8.7%, no significant difference |
| Lee et al., Ann Dermatol, 2016 | 45 men | 6 months | 5-ALA + GHK complex (ALAVAX) 100 or 50 mg/ml vs placebo, once daily | Hair count increase 52.6 and 71.5 vs 9.6 placebo; no change in length or thickness |
| Katoulis et al., Dermatol Ther, 2020 | 44 randomized, 41 completed | 24 weeks | Redensyl + Sepicontrol A5 lotion vs vehicle, twice daily | Active group (n=26) 7.7% great, 73.1% moderate improvement, 19.2% stable |
| Iwabuchi et al., J Cosmet Dermatol, 2016 | 22 men | 4 months | GPIGS pentapeptide lotion vs placebo lotion | More thick hair (P=0.006), less vellus hair (P=0.029), better baldness grading (P=0.020) |
| Tr et al., Cureus, 2023 | 54 men | 4 sessions, 3 weeks apart | Procapil + PRP vs Redensyl, saw palmetto and biotin + PRP | Grading differed (P<0.05); conclusion favored the Redensyl group |
Adil and Godwin, J Am Acad Dermatol, 2017
Result: All superior to placebo (P<.00001)
Systematic review and meta-analysis of good- or fair-quality RCTs; high heterogeneity. Funding not reported in abstract. Evidence: Well-established.
Lueangarun and Panchaprateep, J Clin Aesthet Dermatol, 2020
Result: Terminal hair count +8.3% vs +8.7%, no significant difference
Triple-blind RCT, mild to moderate pattern hair loss, men and women. No placebo arm; blend, not a single peptide. No funding, no conflicts declared. Evidence: Limited.
Lee et al., Ann Dermatol, 2016
Result: Hair count increase 52.6 and 71.5 vs 9.6 placebo; no change in length or thickness
Randomized placebo-controlled; combination product. No adverse events. Funding not reported in abstract. Evidence: Limited.
Katoulis et al., Dermatol Ther, 2020
Result: Active group (n=26) 7.7% great, 73.1% moderate improvement, 19.2% stable
Single-blinded, vehicle-controlled. Vehicle-group results not given in the abstract. No significant adverse events. Funding not reported in abstract. Evidence: Limited.
Iwabuchi et al., J Cosmet Dermatol, 2016
Result: More thick hair (P=0.006), less vellus hair (P=0.029), better baldness grading (P=0.020)
Double-blind RCT in Japanese men, plus lab work. Authors from Shiseido/Frontier Technology Laboratory. Evidence: Early / preliminary.
Tr et al., Cureus, 2023
Result: Grading differed (P<0.05); conclusion favored the Redensyl group
Randomized, blinded photo rater; no peptide-only or placebo arm. No competing interests declared. Evidence: Limited.
No trial in our sources compares any peptide with 5% minoxidil, oral minoxidil or finasteride.
Evidence: Limited.
How do peptides for hair loss compare with minoxidil?
Peptides for hair loss have far less evidence than minoxidil, and only 1 small trial compared the two directly. In that trial, a peptide-containing blend performed about the same as a low-strength 3% minoxidil solution.
Minoxidil's case rests on pooled trials. The 2017 meta-analysis found minoxidil, finasteride and low-level laser therapy all superior to placebo, and noted that minoxidil and finasteride were FDA-approved and the HairMax LaserComb FDA-cleared for pattern hair loss (Adil and Godwin, 2017). A 2026 review still names topical and oral minoxidil, 5-α-reductase inhibitors and oral antiandrogens as the mainstays of treatment (Agrawal et al., 2026).
A 2022 network meta-analysis of 23 studies in men ranked doses and forms against each other (Gupta et al., 2022). For terminal hair count at 24 weeks, 5 mg/day oral minoxidil ranked highest. Conflicts were listed as "none reported," though the first author is affiliated with Mediprobe Research Inc. A 2025 meta-analysis of 4 trials (279 patients, 24 to 39 weeks) found no difference in hair density between oral and topical minoxidil, but hypertrichosis, meaning extra hair growth on the face or body, was about twice as common with oral (RR 2.01) (Sobral et al., 2025).
| Feature | Topical hair peptides | Minoxidil |
|---|---|---|
| Best evidence | Single small RCTs, mostly blends | Meta-analysis of RCTs vs placebo |
| Largest trial in our sources | 45 men (5-ALA + GHK) | Pooled trials; 279 patients in oral vs topical analysis alone |
| FDA status for pattern hair loss | Not among FDA-recognized treatments listed in 2017 | FDA-approved (per 2017 meta-analysis) |
| Direct comparison | 1 trial vs 3% minoxidil, n=32 | No trial vs 5% minoxidil or oral forms |
| Side effects reported | None in the GPIGS, 5-ALA + GHK or tetrapeptide blend trials | 1 scalp eczema case with 3% solution; more hypertrichosis with oral than topical |
| Industry ties | GPIGS trial by Shiseido authors; several trials report no funding | Varies by trial |
Bottom line: Minoxidil has much stronger evidence. Peptide blends are tested mainly as add-ons or alternatives, in small trials.
The 2025 review suggests these topical actives may have a role as an add-on, or for people who can't tolerate standard therapy (Bikash, 2025). That is the author's opinion, not a tested result. Choosing or changing a hair-loss drug is a decision to make with a dermatologist. Evidence: Well-established (minoxidil); Limited (peptides).
Which peptides for hair regrowth have human trials?
3 peptides for hair regrowth have human trial data in our sources: GPIGS, acetyl tetrapeptide-3 (in a blend) and GHK (with 5-ALA). Each was tested in 1 small trial, and 2 of the 3 were combination products.
GPIGS (Gly-Pro-Ile-Gly-Ser) is the only one tested alone against placebo. In 22 Japanese men over 4 months, the change in the share of thick hairs (60 μm or wider) was higher than placebo (P=0.006), and vellus hairs, the fine "peach fuzz" hairs, fell (P=0.029) (Iwabuchi et al., 2016). Blinded reviewers also graded baldness as improved (P=0.020). The authors came from Shiseido, a cosmetics company, and the abstract doesn't report hair counts.
Acetyl tetrapeptide-3 appears only in a blend with biochanin A and ginseng. In a 24-week triple-blind trial of 32 men and women, terminal hair count rose 8.3% with the blend and 8.7% with 3% minoxidil (Lueangarun and Panchaprateep, 2020). With no placebo arm, a small sample and a blend, you can't credit the peptide itself. The study had no funding, and its authors declared no conflicts.
Branded actives often sold with peptides have similar gaps. A Redensyl plus Sepicontrol A5 lotion improved 80.8% of the active group moderately or greatly over 24 weeks, and the anagen-to-telogen ratio (growing vs resting hairs) rose from 2.25 to 6.02 (Katoulis et al., 2020). The trial was single-blinded. Procapil (a branded hair-care active) has no stand-alone trial in our sources; in 54 men, it was paired with platelet-rich plasma (PRP) and the comparison favored the other arm (Tr et al., 2023).
Biotinoyl tripeptide-1, a peptide often listed on hair serum labels, has no published trial testing it on its own in our PubMed search. The closest human data come from branded blends tested alongside other ingredients or PRP, which can't isolate the peptide's effect (Bikash, 2025). Evidence: Limited (no trial of the peptide alone).
For one popular product built on this kind of formula, see our review of The Ordinary's hair density serum. Evidence: Limited.
What about GHK-Cu and AHK-Cu?
Copper-bound peptides have strong lab interest for hair but almost no human hair-loss data of their own. The one human trial used GHK combined with another compound.
In a 6-month randomized trial of 45 men, a complex of 5-aminolevulinic acid (5-ALA) and GHK increased hair count by 52.6 at 100 mg/ml and 71.5 at 50 mg/ml, vs 9.6 with placebo (Lee et al., 2016). Hair length and thickness didn't differ, and no adverse events occurred. The lower dose did better, and funding was not reported.
Show data table
| Group | Hair count increase |
|---|---|
| ALAVAX 50 mg/ml | 71.5hairs |
| ALAVAX 100 mg/ml | 52.6hairs |
| Placebo | 9.6hairs |
A 2008 review lists larger hair follicle size among GHK-Cu effects and says it "improves hair transplant success" (Pickart, 2008). Its author worked for Skin Biology, a company selling GHK-Cu. A 2026 systematic review found about 35% of GHK-Cu primary research includes Skin Biology authors, which it says limits independence (Najafi et al., 2026). It also found no adequately powered human trial of microneedle-delivered GHK-Cu.
AHK-Cu lengthened human hair follicles in a dish at 10⁻¹² to 10⁻⁹ M and stimulated dermal papilla cells (Pyo et al., 2007). No person was treated. Our guide to copper peptides and hair covers this in depth, along with our AHK-Cu peptide explainer and AHK-Cu vs GHK-Cu comparison. Evidence: Limited (GHK combination); Lab / animal only (AHK-Cu).
Are injectable peptides for hair growth proven or safe?
No injectable peptide for hair growth has published human hair results in our sources, and none is FDA-approved for that use. Their hair claims come from animal work or no hair studies at all.
Thymosin beta-4 is a 43-amino-acid protein. It sped hair growth in rats and mice and drove follicle stem cell migration (Philp et al., 2004; Philp et al., 2007). Mice engineered to overproduce it regrew hair faster after hair removal, while knockout mice were slower (Gao et al., 2015). TB-500 is described as a thymosin beta-4 fragment (Mendias and Awan, 2026); no hair study of TB-500 itself is in our sources.
BPC-157 has no hair studies in our sources. A 2025 systematic review found 35 preclinical studies, 1 clinical study and no clinical safety data (Vasireddi et al., 2025). It isn't FDA-approved, and the World Anti-Doping Agency temporarily banned it in 2022 (Jozwiak et al., 2025). Sermorelin has no hair data in our sources either. A 2026 review of peptides marketed direct to patients says "rigorous human safety data are scarce" for unapproved peptides, with "potential for serious harm" (Mendias and Awan, 2026).
PP405 appears in a 2026 review as one of the "metabolic and follicular activators" in development (Agrawal et al., 2026). Its results haven't been published in a peer-reviewed journal in our sources. Separately, a 2017 mouse study found that lactate production drives hair follicle stem cell activation; its authors hold related patents, and it doesn't test PP405 (Flores et al., 2017). Evidence: Lab / animal only.
Do peptides help gray hair?
No peptide has been shown to visibly restore hair color. Reviews state that effective, evidence-based treatments for premature graying are still lacking (Poonia and Bhalla, 2024) and that camouflage remains the primary treatment (Triwongwaranat et al., 2019).
Palmitoyl tetrapeptide-20 mimics α-MSH, a hormone that switches on pigment production. In lab and donated-hair tests, it raised the antioxidant enzyme catalase, cut hydrogen peroxide by 30% and boosted melanin (Almeida Scalvino et al., 2018). In 15 men with premature graying, a 10 ppm lotion used daily for 3 months raised MC1-R, a pigment-related receptor protein, in plucked hairs. The study reported no visible repigmentation, had no placebo group in the abstract, and was funded by a French state grant. Evidence: Early / preliminary.
How long do peptides for hair growth take to show results?
The human trials of peptides for hair growth ran 4 to 6 months before reporting their main results. No trial in our sources reported a clear benefit within the first month.
When hair peptide and minoxidil studies checked results
- Month 1First check
5-ALA + GHK trial's first assessment; main results came at 6 months (Lee).
- 12 weeksGrowing-hair ratio rises
Anagen-to-telogen ratio 2.25 to 4.00 with Redensyl + Sepicontrol A5 (Katoulis).
- 4 monthsGPIGS endpoint
More thick hair vs placebo (Iwabuchi).
- 24 weeksBlend vs minoxidil
Terminal hair +8.3% vs +8.7% with 3% minoxidil (Lueangarun); ratio reaches 6.02 (Katoulis).
- 6 monthsGHK combination endpoint
Hair count up 52.6 and 71.5 vs 9.6 placebo (Lee).
- 48 weeksLongest drug endpoints
Minoxidil and finasteride ranked at 24 and 48 weeks (Gupta).
No study tracked what happens to peptide-driven gains after people stop, and none ran longer than 6 months. A "results in 8 weeks" claim on a product page doesn't match any trial in our sources. Evidence: Limited.
Where do peptide hair serums fit if you're losing hair?
A peptide serum is, at best, a small-evidence cosmetic option, and it can't tell you why your hair is thinning. Pattern hair loss, shedding after illness or weight loss, and other causes need a diagnosis first.
No study in our sources tests a peptide serum layered with minoxidil, finasteride or PRP alone, so any combination advice is clinic convention. If your shedding started on a GLP-1 drug, our guides to Ozempic hair loss and tirzepatide hair loss cover that separate question. Talk to a dermatologist before adding anything to, or changing, a hair-loss treatment. Evidence: no studies.
Where the evidence stops
- No peptide has more than 1 human trial in our sources, and the largest enrolled 45 people.
- Most trials tested blends or combinations, so single-peptide effects are unknown.
- No trial compares peptides with 5% or oral minoxidil, or with finasteride.
- No human hair-loss trial of GHK-Cu or AHK-Cu alone.
- Injectable peptides have no human hair data, and safety data are scarce.
- No data on women specifically, long-term use, stopping, or results beyond 6 months. For thinning around menopause, see our menopause hair loss guide.
- Gray hair peptides show no visible color change in any study we found.
FAQ
Do peptides for hair growth actually work?
A few small human trials suggest some topical peptides can modestly improve pattern hair loss. The largest single-ingredient placebo trial in our sources had only 22 men, and none comes close to the meta-analysis evidence behind minoxidil.
Which peptide has the best evidence for hair loss?
The GPIGS pentapeptide has a double-blind placebo-controlled trial in 22 Japanese men, which found more thick hair after 4 months; the authors worked for Shiseido. A blend containing acetyl tetrapeptide-3 matched 3% minoxidil in a 32-person trial, but it mixed the peptide with other extracts and had no placebo arm.
Are hair peptides as good as minoxidil?
Only 1 trial in our sources compared them directly: a blend with acetyl tetrapeptide-3, biochanin A and ginseng gave an 8.3% rise in terminal hair count vs 8.7% for 3% minoxidil over 24 weeks, with no significant difference. That trial had 32 people, no placebo arm, and did not test 5% minoxidil.
Does GHK-Cu regrow hair?
No human trial of GHK-Cu alone for hair loss is in our sources. The one human trial tested GHK combined with 5-aminolevulinic acid in 45 men and found higher hair counts than placebo at 6 months, so the peptide's own effect can't be separated out.
Is TB-500 or BPC-157 good for hair growth?
Thymosin beta-4, the protein TB-500 is a fragment of, grew hair faster in mice and rats, but no human hair study of it is in our sources. We found no hair studies of BPC-157 at all, and neither peptide is FDA-approved.
Can peptides reverse gray hair?
No study in our sources shows visible repigmentation from a peptide. A 2018 study of palmitoyl tetrapeptide-20 in 15 men with premature graying measured a pigment-related receptor protein in plucked hairs, not color, and reviews say effective evidence-based gray hair treatments are still lacking.
How long do hair growth peptides take to work?
The human peptide trials ran 4 to 6 months before reporting their main results, and none reported a clear benefit at 1 month. No study in our sources tracked what happens after people stop using a hair peptide.
Can I use a peptide hair serum with minoxidil?
No study in our sources tested a peptide serum layered with minoxidil, so we can't say whether the combination adds anything or causes problems. Talk to a dermatologist before adding anything to a hair-loss treatment you already use.
References
- Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017. Systematic review and meta-analysis of RCTs; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/28396101/
- Gupta AK, et al. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022. Network meta-analysis, 23 studies; first author affiliated with Mediprobe Research Inc; conflicts "none reported." https://pubmed.ncbi.nlm.nih.gov/35107565/
- Sobral MVS, et al. Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. Int J Dermatol. 2025. Meta-analysis, 4 RCTs, 279 patients, 24 to 39 weeks; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/39425514/
- Agrawal A, et al. Emerging pharmacotherapies for androgenetic alopecia. Expert Opin Pharmacother. 2026. Targeted review; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/42290527/
- Lee WJ, et al. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Ann Dermatol. 2016. Randomized placebo-controlled trial, n=45 men, 6 months; funding not reported. https://pubmed.ncbi.nlm.nih.gov/27489425/
- Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. Ex vivo human follicles and cultured cells; non-US government support. https://pubmed.ncbi.nlm.nih.gov/17703734/
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. Review; author affiliated with Skin Biology, a commercial GHK-Cu company. https://pubmed.ncbi.nlm.nih.gov/18644225/
- Najafi N, et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026. Systematic review, 64 records; authors declare no conflict. https://pubmed.ncbi.nlm.nih.gov/42787770/
- Lueangarun S, Panchaprateep R. An Herbal Extract Combination (Biochanin A, Acetyl tetrapeptide-3, and Ginseng Extracts) versus 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A 24-week, Prospective, Randomized, Triple-blind, Controlled Trial. J Clin Aesthet Dermatol. 2020. Triple-blind RCT, n=32, 24 weeks; no funding, no conflicts. https://pubmed.ncbi.nlm.nih.gov/33584955/
- Katoulis AC, et al. A randomized, single-blinded, vehicle-controlled study of a topical active blend in the treatment of androgenetic alopecia. Dermatol Ther. 2020. Single-blind RCT, 44 randomized, 41 completed, 24 weeks; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/32473084/
- Tr P, et al. A Comparative Study of Topical Procapil With Platelet-Rich Plasma Therapy Versus Topical Redensyl, Saw Palmetto, and Biotin With Platelet-Rich Plasma Therapy in the Treatment of Androgenetic Alopecia. Cureus. 2023. RCT, n=54 men, 4 sessions; no competing interests declared. https://pubmed.ncbi.nlm.nih.gov/37292551/
- Bikash C. Topical Alternatives for Hair Loss: Beyond the Conventional. Int J Trichology. 2025. Review of 24 articles and technical files; no conflicts. https://pubmed.ncbi.nlm.nih.gov/40654553/
- Iwabuchi T, et al. The topical penta-peptide Gly-Pro-Ile-Gly-Ser increases the proportion of thick hair in Japanese men with androgenetic alopecia. J Cosmet Dermatol. 2016. Double-blind RCT, n=22, 4 months, plus lab work; authors from Shiseido/Frontier Technology Laboratory. https://pubmed.ncbi.nlm.nih.gov/27030543/
- Flores A, et al. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nat Cell Biol. 2017. Mouse and lab study; UC Regents patents, one author a Carthronix LLC shareholder. https://pubmed.ncbi.nlm.nih.gov/28812580/
- Philp D, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004. Rat and mouse study; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/14657002/
- Philp D, et al. Thymosin beta 4 induces hair growth via stem cell migration and differentiation. Ann N Y Acad Sci. 2007. Rat and mouse models; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/17947589/
- Gao X, et al. Thymosin Beta-4 Induces Mouse Hair Growth. PLoS One. 2015. Transgenic and knockout mouse study; non-US government support; no competing interests. https://pubmed.ncbi.nlm.nih.gov/26083021/
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. Narrative review; one author consults for Arthrex on unrelated work. https://pubmed.ncbi.nlm.nih.gov/41966639/
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. Systematic review, 36 studies (35 preclinical, 1 clinical); several authors report orthopedic industry relationships. https://pubmed.ncbi.nlm.nih.gov/40756949/
- Józwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025. Literature and patent review; no conflicts. https://pubmed.ncbi.nlm.nih.gov/40005999/
- Poonia K, Bhalla M. Premature Graying of Hair: A Comprehensive Review and Recent Insights. Indian Dermatol Online J. 2024. Review; no conflicts. https://pubmed.ncbi.nlm.nih.gov/39359282/
- Triwongwaranat D, et al. A review of the etiologies, clinical characteristics, and treatment of canities. Int J Dermatol. 2019. Review; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/30768676/
- Almeida Scalvino S, et al. Efficacy of an agonist of α-MSH, the palmitoyl tetrapeptide-20, in hair pigmentation. Int J Cosmet Sci. 2018. Lab and ex vivo work plus clinical study, n=15 men, 3 months; French state grant (FUI). https://pubmed.ncbi.nlm.nih.gov/30222197/
Disclosure: This article is for general information only. It is not medical advice. Peptide Skincare has no affiliate links in this article and received no payment from any manufacturer mentioned. Hair loss can have medical causes; see a dermatologist for diagnosis, and talk to a prescriber before starting or changing any hair-loss medication. Injectable research peptides are not FDA-approved.